Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,284.77
+5.63 (+0.44%)
Delayed Quote
Updated: 12:08 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
↗
October 26, 2026
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Via
MarketBeat
Topics
Artificial Intelligence
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
↗
October 26, 2026
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV?
↗
October 26, 2026
XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.
Via
The Motley Fool
Topics
ETFs
Stocks
Eli Lilly & Co (NYSE:LLY) Offers Dividend Quality for Growth-Focused Income Investors
↗
October 19, 2026
Via
Chartmill
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?
↗
October 25, 2026
Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.
Via
The Motley Fool
Topics
Intellectual Property
The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.
↗
October 24, 2026
Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.
Via
The Motley Fool
Topics
Artificial Intelligence
Stocks
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)
↗
October 23, 2026
These drugmakers are capitalizing on their pipeline successes.
Via
The Motley Fool
Topics
Artificial Intelligence
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader
↗
October 23, 2026
Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.
Via
Investor's Business Daily
Topics
Artificial Intelligence
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
↗
October 23, 2026
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via
MarketBeat
The S&P 500 May Depend on the Fortunes of These 3 Companies Right Now. Here’s the Good News and the Bad News for Investors.
↗
October 23, 2026
These companies make up about 20% of the index.
Via
The Motley Fool
Topics
Economy
Stocks
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
October 22, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
↗
October 22, 2026
Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
Via
The Motley Fool
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
↗
October 22, 2026
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.
Via
The Motley Fool
Topics
Artificial Intelligence
Lawsuit
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF
↗
October 21, 2026
VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.
Via
The Motley Fool
Topics
ETFs
Where Will Novo Stock Be in 10 Years?
↗
October 21, 2026
The company may lean on its core therapeutic area to help it overcome recent headwinds.
Via
The Motley Fool
Topics
Intellectual Property
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
↗
October 21, 2026
Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026
↗
October 21, 2026
The market has rewarded this biotech for its breakthroughs.
Via
The Motley Fool
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
↗
October 21, 2026
Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.
Via
The Motley Fool
Here's What I'm Planning With My Eli Lilly Position
↗
October 20, 2026
The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors.
Via
The Motley Fool
Topics
Economy
Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%
↗
October 20, 2026
On Oct. 20, 2026, major U.S. indexes gained as falling oil prices boosted blue chips and semiconductors edged upwards.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
Stocks
S&P 500 Top Movers: Gainers and Losers From Today's US Session
↗
October 20, 2026
Via
Chartmill
Topics
Stocks
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
October 20, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
Topics
Energy
Is Eli Lilly Stock a Buy Right Now?
↗
October 19, 2026
Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.
Via
The Motley Fool
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
↗
October 19, 2026
Is this company the biggest dark horse in the chronic weight management space?
Via
The Motley Fool
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
↗
October 19, 2026
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via
MarketBeat
Topics
Artificial Intelligence
What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs
↗
October 19, 2026
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.
Via
MarketBeat
Topics
ETFs
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
↗
October 19, 2026
Buffett has warned about "gambling" in the market.
Via
The Motley Fool
Topics
Intellectual Property
Retirement
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
↗
October 18, 2026
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
Via
The Motley Fool
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
↗
October 18, 2026
Novo is facing some headwinds, but it has a plan to overcome them.
Via
The Motley Fool
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.
↗
October 18, 2026
It was Griffin's biggest add for Citadel last quarter.
Via
The Motley Fool
Topics
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
